Comparison tool

CagriSema vs Tirzepatide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

CagriSemaTirzepatide

Share this peptide comparison

Property	CagriSema	Tirzepatide
Category	Weight Loss	Weight Loss
Also known as	Semaglutide + Cagrilintide	Mounjaro, Zepbound, LY3298176
FDA approved	No	Yes
Clinical status	NDA submitted Dec 18, 2025; FDA decision expected Q4 2026. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Maximum weight loss, combination therapy, obesity	Weight loss, diabetes management, metabolic health
How it works	CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone.	Tirzepatide is described as a dual agonist of GIP and GLP-1 receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved.
Typical dosing	Limited community data available · See research protocols	5-15 mg weekly (after titration) · Once weekly
Research dosing	Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly	2.5mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly
Typical duration	Long-term use expected	Long-term / chronic use
Administration	Subcutaneous injection weekly	Subcutaneous injection weekly
Timing	-	Morning, same day each week With or without food
Evidence level	Clinical Trials	FDA Approved
Possible side effects	Nausea (Reported as a gastrointestinal adverse effect in the source.) Vomiting (Reported as a gastrointestinal adverse effect in the source.) Diarrhea (Reported as a gastrointestinal adverse effect in the source.) +4 more Constipation (Reported as a gastrointestinal adverse effect in the source.) Gastrointestinal events (The source reports 72-80% with CagriSema compared with 34-40% for placebo.) Higher gastrointestinal effects than semaglutide alone (Listed in the source side-effect field.) Investigational status (The source notes that CagriSema is not yet approved.)	Nausea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.) Diarrhea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.) Vomiting (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.) +9 more Constipation (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.) Decreased appetite (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.) Abdominal pain (Listed in the source adverse-effect information.) Injection site reactions (Listed in the source adverse-effect information.) Hypoglycemia (with insulin/sulfonylureas) (The source specifically gives the insulin/sulfonylurea context.) Pancreatitis (Listed in the source adverse-effect information.) Gallbladder problems (Listed in the source adverse-effect information.) Acute kidney injury (Listed in the source adverse-effect information.) Thyroid C-cell tumors (The source labels this a BOXED WARNING and states a contraindication with MTC/MEN 2.)
Research summary	The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects.	The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results.
References	New England Journal of Medicine New England Journal of Medicine +2 more American Diabetes Association Novo Nordisk	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

CagriSema

Tirzepatide

Category

Weight Loss

Also known as

Semaglutide + Cagrilintide

Mounjaro, Zepbound, LY3298176

FDA approved

Yes

Clinical status

NDA submitted Dec 18, 2025; FDA decision expected Q4 2026.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Maximum weight loss, combination therapy, obesity

Weight loss, diabetes management, metabolic health

How it works

CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone.

Tirzepatide is described as a dual agonist of GIP and GLP-1 receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved.

Typical dosing

Limited community data available · See research protocols

5-15 mg weekly (after titration) · Once weekly

Research dosing

Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly

2.5mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly

Typical duration

Long-term use expected

Long-term / chronic use

Administration

Subcutaneous injection weekly

Timing

Morning, same day each week

With or without food

Evidence level

Clinical Trials

FDA Approved

Possible side effects

Nausea (Reported as a gastrointestinal adverse effect in the source.)
Vomiting (Reported as a gastrointestinal adverse effect in the source.)
Diarrhea (Reported as a gastrointestinal adverse effect in the source.)

+4 more

Constipation (Reported as a gastrointestinal adverse effect in the source.)
Gastrointestinal events (The source reports 72-80% with CagriSema compared with 34-40% for placebo.)
Higher gastrointestinal effects than semaglutide alone (Listed in the source side-effect field.)
Investigational status (The source notes that CagriSema is not yet approved.)

Nausea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.)
Diarrhea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.)
Vomiting (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.)

+9 more

Constipation (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.)
Decreased appetite (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.)
Abdominal pain (Listed in the source adverse-effect information.)
Injection site reactions (Listed in the source adverse-effect information.)
Hypoglycemia (with insulin/sulfonylureas) (The source specifically gives the insulin/sulfonylurea context.)
Pancreatitis (Listed in the source adverse-effect information.)
Gallbladder problems (Listed in the source adverse-effect information.)
Acute kidney injury (Listed in the source adverse-effect information.)
Thyroid C-cell tumors (The source labels this a BOXED WARNING and states a contraindication with MTC/MEN 2.)

Research summary

The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects.

The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results.

References

New England Journal of Medicine New England Journal of Medicine

+2 more

American Diabetes Association Novo Nordisk

Source Source

+2 more

Source Source

Full profile

View Details